Index RUT
P/E -
EPS (ttm) -1.50
Insider Own 24.32%
Shs Outstand 120.71M
Perf Week -6.86%
Market Cap 543.42M
Forward P/E -
EPS next Y -0.71
Insider Trans -0.23%
Shs Float 91.80M
Perf Month -7.63%
Income -171.67M
PEG -
EPS next Q -0.18
Inst Own 71.11%
Short Float 9.51%
Perf Quarter 96.49%
Sales 36.85M
P/S 14.75
EPS this Y 56.12%
Inst Trans 4.10%
Short Ratio 3.75
Perf Half Y 258.40%
Book/sh 0.31
P/B 14.65
EPS next Y -9.10%
ROA -61.27%
Short Interest 8.73M
Perf Year 9.27%
Cash/sh 1.72
P/C 2.60
EPS next 5Y -
ROE -266.24%
52W Range 0.80 - 9.62
Perf YTD 93.10%
Dividend Est. -
P/FCF -
EPS past 5Y 11.93%
ROI -263.08%
52W High -53.43%
Beta 1.48
Dividend TTM -
Quick Ratio 3.36
Sales past 5Y 12371.94%
Gross Margin 95.88%
52W Low 459.02%
ATR (14) 0.41
Dividend Ex-Date -
Current Ratio 3.36
EPS Y/Y TTM 31.64%
Oper. Margin -463.86%
RSI (14) 45.00
Volatility 7.39% 8.99%
Employees 123
Debt/Eq 0.92
Sales Y/Y TTM 38.65%
Profit Margin -465.80%
Recom 1.50
Target Price 6.57
Option/Short Yes / Yes
LT Debt/Eq 0.77
EPS Q/Q 63.57%
Payout -
Rel Volume 0.60
Prev Close 4.49
Sales Surprise -27.40%
EPS Surprise 0.12%
Sales Q/Q -27.14%
Earnings Feb 28 BMO
Avg Volume 2.33M
Price 4.48
SMA20 -14.35%
SMA50 6.20%
SMA200 70.98%
Trades
Volume 1,397,862
Change -0.22%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-19-24 Upgrade
JP Morgan
Underweight → Neutral
$5
Feb-29-24 Upgrade
Wedbush
Neutral → Outperform
$2 → $7
Feb-29-24 Upgrade
Guggenheim
Neutral → Buy
$7
Feb-29-24 Upgrade
BTIG Research
Neutral → Buy
$6
Dec-04-23 Upgrade
Citigroup
Neutral → Buy
$1 → $5
Jul-28-23 Downgrade
Robert W. Baird
Outperform → Neutral
$7 → $1
Jul-27-23 Downgrade
Wedbush
Outperform → Neutral
Jul-27-23 Downgrade
Truist
Buy → Hold
Jul-27-23 Downgrade
JP Morgan
Neutral → Underweight
Jul-27-23 Downgrade
Guggenheim
Buy → Neutral
Jul-27-23 Downgrade
Citigroup
Buy → Neutral
Jul-27-23 Downgrade
BTIG Research
Buy → Neutral
Jun-16-23 Downgrade
JP Morgan
Overweight → Neutral
$11 → $5
Jun-15-23 Initiated
Guggenheim
Buy
$14
Mar-16-23 Upgrade
JP Morgan
Neutral → Overweight
$10
Jan-20-23 Initiated
Citigroup
Buy
$12
Nov-21-22 Initiated
Truist
Buy
$12
Oct-15-21 Resumed
BTIG Research
Buy
$32
Aug-30-21 Initiated
H.C. Wainwright
Buy
$28
Mar-31-21 Initiated
Credit Suisse
Neutral
$18
Show Previous Ratings
Feb-29-24 08:41AM
Feb-28-24 09:49PM
(Thomson Reuters StreetEvents) +13.58%
08:10AM
07:35AM
07:00AM
08:01AM
Loading…
Feb-27-24 08:01AM
Feb-21-24 08:00AM
Feb-20-24 10:00AM
Feb-01-24 08:00AM
Jan-05-24 08:01AM
Dec-01-23 04:30PM
Nov-08-23 02:42PM
12:13AM
(Thomson Reuters StreetEvents)
Nov-07-23 08:10AM
07:00AM
04:30PM
Loading…
Oct-31-23 04:30PM
08:00AM
Sep-07-23 06:30AM
(American City Business Journals)
Sep-06-23 07:00AM
Aug-18-23 09:35AM
Aug-16-23 09:35AM
Aug-08-23 09:40AM
08:00AM
Aug-04-23 04:05PM
Jul-28-23 10:13AM
03:14AM
Jul-27-23 09:34PM
01:44PM
(American City Business Journals)
07:06AM
Jul-13-23 09:45AM
04:05PM
Loading…
Jul-06-23 04:05PM
Jun-22-23 11:04AM
Jun-16-23 10:43AM
02:26AM
Jun-15-23 09:32AM
07:36AM
07:30AM
Jun-13-23 06:00AM
Jun-02-23 04:05PM
May-28-23 09:06AM
May-24-23 08:00AM
May-09-23 08:35AM
07:00AM
May-04-23 04:05PM
May-03-23 08:00AM
May-02-23 08:00AM
Apr-26-23 04:05PM
Apr-19-23 02:42PM
Apr-17-23 11:07AM
Apr-06-23 04:05PM
Apr-05-23 02:00PM
Mar-16-23 11:20AM
Mar-13-23 02:00PM
07:54AM
07:30AM
Mar-10-23 07:10PM
Mar-03-23 04:05PM
Mar-02-23 08:55PM
Mar-01-23 05:24AM
Feb-28-23 11:51PM
(Thomson Reuters StreetEvents) +11.60%
07:00AM
Feb-21-23 08:00AM
Feb-03-23 04:05PM
Feb-02-23 08:00AM
Feb-01-23 08:00AM
Jan-25-23 08:00AM
Jan-20-23 03:16PM
Jan-16-23 02:18AM
Jan-06-23 04:05PM
07:00AM
Dec-31-22 07:42AM
Dec-23-22 12:46PM
(American City Business Journals)
10:08AM
Dec-22-22 04:08PM
04:05PM
Dec-14-22 08:00AM
Dec-02-22 04:05PM
Nov-08-22 08:00AM
Nov-07-22 08:25AM
07:00AM
Nov-04-22 04:05PM
Oct-31-22 08:00AM
Oct-30-22 10:13AM
Oct-17-22 09:40AM
Oct-06-22 04:05PM
Oct-04-22 04:05PM
Sep-30-22 08:02AM
Sep-12-22 08:00AM
Sep-06-22 08:00AM
Sep-02-22 04:05PM
Sep-01-22 10:17AM
Aug-16-22 09:55AM
08:00AM
Aug-12-22 06:05AM
Aug-11-22 11:25AM
Aug-09-22 06:58AM
Aug-08-22 05:15PM
04:04PM
04:02PM
Aug-04-22 04:05PM
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Protopapas Anna Director Jan 16 '24 Sale 2.71 29,399 79,671 125,153 Jan 17 05:21 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 16 '24 Sale 2.71 10,409 28,208 199,329 Jan 17 05:19 PM DeSchuytner Brian SVP, COO & CFO Jan 16 '24 Sale 2.71 9,327 25,276 54,511 Jan 17 05:18 PM Mandelia Ashish VP, Chief Accounting Officer Jan 16 '24 Sale 2.71 5,025 13,618 23,328 Jan 17 05:20 PM Carvajal Alejandra SVP, Chief Legal Officer Jan 16 '24 Sale 2.71 4,381 11,873 27,403 Jan 17 05:18 PM Bala Mohan SVP, Chief Development Officer Jan 16 '24 Sale 2.71 3,431 9,298 14,052 Jan 17 05:16 PM MISRA TUSHAR SVP, Chief Manuf. Officer Jan 16 '24 Sale 2.71 3,357 9,097 17,966 Jan 17 05:21 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 15 '24 Option Exercise 0.00 15,208 0 209,738 Jan 17 05:19 PM DeSchuytner Brian SVP, COO & CFO Jan 15 '24 Option Exercise 0.00 10,208 0 63,838 Jan 17 05:18 PM Protopapas Anna Director Jan 15 '24 Option Exercise 0.00 38,958 0 154,552 Jan 17 05:21 PM Mandelia Ashish VP, Chief Accounting Officer Jan 15 '24 Option Exercise 0.00 5,352 0 28,353 Jan 17 05:20 PM Mandelia Ashish VP, Chief Accounting Officer Jan 14 '24 Option Exercise 0.00 4,783 0 23,001 Jan 17 05:20 PM MISRA TUSHAR SVP, Chief Manuf. Officer Jan 14 '24 Option Exercise 0.00 1,458 0 21,323 Jan 17 05:21 PM Protopapas Anna Director Jan 14 '24 Option Exercise 0.00 16,750 0 115,594 Jan 17 05:21 PM Carvajal Alejandra SVP, Chief Legal Officer Jan 14 '24 Option Exercise 0.00 2,500 0 31,784 Jan 17 05:18 PM DeSchuytner Brian SVP, COO & CFO Jan 14 '24 Option Exercise 0.00 6,250 0 55,630 Jan 17 05:18 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 14 '24 Option Exercise 0.00 4,792 0 194,530 Jan 17 05:19 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 13 '24 Option Exercise 0.00 9,375 0 189,738 Jan 17 05:19 PM DeSchuytner Brian SVP, COO & CFO Jan 13 '24 Option Exercise 0.00 10,000 0 47,380 Jan 17 05:18 PM Carvajal Alejandra SVP, Chief Legal Officer Jan 13 '24 Option Exercise 0.00 8,958 0 29,284 Jan 17 05:18 PM Bala Mohan SVP, Chief Development Officer Jan 13 '24 Option Exercise 0.00 8,750 0 17,483 Jan 17 05:16 PM Protopapas Anna Director Jan 13 '24 Option Exercise 0.00 31,250 0 98,844 Jan 17 05:21 PM MISRA TUSHAR SVP, Chief Manuf. Officer Jan 13 '24 Option Exercise 0.00 7,083 0 19,865 Jan 17 05:21 PM Mandelia Ashish VP, Chief Accounting Officer Jan 13 '24 Option Exercise 0.00 2,645 0 18,218 Jan 17 05:20 PM Bala Mohan SVP, Chief Development Officer Oct 26 '23 Sale 1.13 1,912 2,161 8,733 Oct 27 04:07 PM Bala Mohan SVP, Chief Development Officer Oct 25 '23 Option Exercise 0.00 6,250 0 10,645 Oct 27 04:07 PM MISRA TUSHAR SVP, Chief Manuf. Officer Aug 17 '23 Sale 1.18 1,908 2,251 11,507 Aug 18 04:01 PM MISRA TUSHAR SVP, Chief Manuf. Officer Aug 16 '23 Option Exercise 0.00 6,250 0 13,415 Aug 18 04:01 PM Carvajal Alejandra SVP, Chief Legal Officer Apr 27 '23 Sale 3.89 3,944 15,342 20,326 Apr 28 04:15 PM Carvajal Alejandra SVP, Chief Legal Officer Apr 26 '23 Option Exercise 0.00 13,250 0 24,270 Apr 28 04:15 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite